Clinical Trials

Phase 2 Not yet recruiting

HER2-positive Breast Cancer

NCT06998771 2025-05-31

JSKN003 Combined Treatment of HER2-positive Gastric Cancer

153 enrolled

Phase 2 Not yet recruiting

HER2-positive Gastric Cancer

NCT06589830 2025-05-15

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

80 enrolled

Neoplasms, Colorectal Neoplasms

NCT02091960 2025-04-04

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

103 enrolled 17 charts

Breast Neoplasms

NCT04632992 2025-01-08

MyTACTIC

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT02675231 2024-11-26

monarcHER

237 enrolled 25 charts

Hormone Receptor Positive Breast Cancer

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

117 enrolled 21 charts 2 FDA

Colorectal Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT02291289 2024-05-06

MODUL

1,044 enrolled 21 charts

Colorectal Neoplasms

NCT03272477 2024-04-17

TP-II

257 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04908813 2024-04-15

Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

150 enrolled

Stomach Neoplasms

NCT01953926 2024-03-12

SUMMIT

582 enrolled 27 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT03321981 2024-03-07

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

105 enrolled 23 charts

Lethal Congenital Contracture Syndrome 2

NCT00712881 2024-02-23

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

126 enrolled 16 charts

Breast Neoplasms

NCT03674112 2024-01-02

PHranceSCa

160 enrolled 53 charts

HER2-Positive Early Breast Cancer

NCT02297698 2023-12-12

HER3+

100 enrolled 11 charts

Breast Neoplasms

NCT04262804 2023-08-22

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Phase 2 Unknown

123 enrolled

Breast Cancer Metastatic

NCT02614794 2023-08-14

HER2CLIMB

612 enrolled 30 charts 3 FDA

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02229149 2022-12-02

Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer

33 enrolled

Breast Neoplasms

NCT02000882 2022-02-07

STAR Cape+BKM120 MBC With Brain Met

10 enrolled 11 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02536339 2021-12-07

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

40 enrolled 34 charts

Breast Neoplasms

NCT02213042 2021-10-13

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

42 enrolled 13 charts

Breast Neoplasms

NCT02132949 2021-09-17

BERENICE

401 enrolled 24 charts

Breast Neoplasms

NCT01220128 2021-05-25

INDUCT

66 enrolled 40 charts

Breast Neoplasms

NCT01402401 2020-12-10

Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

21 enrolled

Stomach Neoplasms

NCT01570036 2020-12-02

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

275 enrolled 23 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01491737 2020-10-28

PERTAIN

258 enrolled 18 charts

Breast Neoplasms

NCT00093145 2019-11-25

Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

32 enrolled 19 charts

Breast Neoplasms

NCT01816594 2019-11-14

NeoPHOEBE

50 enrolled 23 charts

Breast Neoplasms

NCT01748773 2019-10-09

TOXAG

34 enrolled

Stomach Neoplasms

NCT00915018 2018-08-22

NEFERTT

479 enrolled 13 charts

Breast Neoplasms

NCT01461057 2018-08-09

JOSHUA

30 enrolled 9 charts

Stomach Neoplasms

NCT00687440 2018-07-03

A Study to Determine the Activity of Caelyx With Trastuzumab and Docetaxel in the Treatment of Metastatic Breast Cancer (Study P03679)

27 enrolled 5 charts

Breast Neoplasms

NCT00885755 2018-03-29

A Study of Herceptin (Trastuzumab)and Biomarkers in Patients With HER2-Positive Metastatic Breast Cancer

33 enrolled 15 charts

Breast Neoplasms

NCT01142778 2018-03-16

AVATAXHER

152 enrolled

Breast Neoplasms

NCT00545688 2017-08-15

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

417 enrolled 25 charts

Breast Neoplasms

NCT01774851 2017-06-22

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

84 enrolled 10 charts

Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

NCT00550771 2017-06-07

Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

181 enrolled 9 charts

Breast Neoplasms

NCT01205217 2017-06-07

ELATE

Phase 2 Withdrawn

Breast Neoplasms

NCT01401166 2017-03-06

PrefHER

488 enrolled 13 charts

Breast Neoplasms

NCT00976989 2017-02-06

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

225 enrolled 19 charts